While the JNK pathway is prevalently viewed as one of the IL-17A-induced signaling pathways, the role of JNK1 and JNK2 isoforms in mediating IL-17/IL-17R-controlled tumor-specific responses has never been investigated. This evidence concerns the gene MAPK9 and neoplasm.